Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2

Mishra, S; Pertz, V; Zhang, B; Kaur, P; Shimada, H; Groffen, J; Kazimierczuk, Z; Pinna, Lorenzo; Heisterkamp, N.

doi:10.1038/sj.leu.2404460

Taken together, the results presented show that inhibitors of the serine/threonine kinase CK2 may be useful either as monotherapy or even more potent in combination therapy with the tyrosine kinase inhibitor, Imatinib, for the treatment of leukemias caused by the Bcr/Abl oncogene. In the preclinical model used here, we have shown that especially the combination of the two drugs may be useful in eradicating cells that appear to linger after the initial treatment with a single drug,

Titolo:	Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2
Autori:	MISHRA S PERTZ V ZHANG B KAUR P SHIMADA H GROFFEN J KAZIMIERCZUK Z PINNA, LORENZO HEISTERKAMP N. mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2007
Rivista:	LEUKEMIA
Abstract:	Taken together, the results presented show that inhibitors of the serine/threonine kinase CK2 may be useful either as monotherapy or even more potent in combination therapy with the tyrosine kinase inhibitor, Imatinib, for the treatment of leukemias caused by the Bcr/Abl oncogene. In the preclinical model used here, we have shown that especially the combination of the two drugs may be useful in eradicating cells that appear to linger after the initial treatment with a single drug,
Handle:	http://hdl.handle.net/11577/1775627
Appare nelle tipologie:	01.01 - Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11577/1775627

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.